Skip to main content
Caplight Logo









CubaseBio

CubaseBio

Private
StockholmHealthcare & Life Scienceshttps://www.cubasebio.com/

Last Round

Grant

Feb 17, 2026

Total Funding Raised

$2.37M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

CubaseBio is a biotechnology company that develops tools for 3D spatial analysis at scale, designed to accelerate drug discovery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Hardware + Subscription, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

3D spatial transcriptomicsDNA microscopyspatial biologyspatial omicsorganoid analysisgene expression mappingdrug discovery toolsvolumetric spatial biologylife science toolsin situ analysisbiotech equipmentbioinformatics softwareresearch kits

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CubaseBio Comparables

Compare CubaseBio with similar companies based on industry and business-model similarity.

CubaseBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stellaromics
80%
Resolve Biosciences
78%
10X Genomics
74%

CubaseBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 17, 2026
VC RoundFeb 17, 2026

CubaseBio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 17, 2026

    $4.6M round led by Nordic Science Investments and Voima Ventures.

  • Feb 17, 2026

    Secured $2.37M in grant funding from the European Innovation Council.

Recent news

Latest coverage and updates

  • is_developingSep 9, 2026

    Cubase Bio AB is developing technologies for cardiovascular drug discovery on Sep 9th '26.

CubaseBio Filings

Explore SEC and related filing metadata, where available.

CubaseBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about CubaseBio's valuation, stock price, and market status.

Is CubaseBio a public or private company?

CubaseBio is a private company.

What is the current stock price of CubaseBio?

CubaseBio is a private company with no public stock price. No recent secondary market data is available.

How much is CubaseBio worth (valuation)?

Valuation information for CubaseBio is not publicly available.

Can I buy CubaseBio stock?

CubaseBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was CubaseBio's last funding round?

CubaseBio's most recent funding round was Grant on February 17, 2026.

Who are the main investors in CubaseBio?

Key investors in CubaseBio include Nordic Science Investments, Voima Ventures.

Will CubaseBio IPO soon?

No public IPO plans have been announced for CubaseBio.

How can I track CubaseBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CubaseBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStockholm
Year Founded2024
Last FundingFeb 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?